Defunct Company
Total Trials
11
As Lead Sponsor
As Collaborator
0
Total Enrollment
1,245
NCT01648322
Dose-Finding Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy
Phase: Phase 2
Role: Lead Sponsor
Start: Jun 30, 2012
Completion: Dec 31, 2014
NCT02527746
Study of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy
Phase: Phase 1
Start: Dec 31, 2012
Completion: Dec 31, 2013
NCT02522234
A Pharmacokinetics/Dynamics Ib Study of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy
Phase: Phase 1/2
Start: Feb 25, 2014
Completion: Aug 19, 2015
NCT02521441
A Phase II, Dose-finding Study of F-627 in Patients With Breast Cancer Receiving Myelotoxic Chemotherapy.
Start: Jul 3, 2014
Completion: Dec 22, 2015
NCT02406651
Study of IL-22 IgG2-Fc (F-652) for Subjects With Grade II-IV Lower GI aGVHD
Start: May 12, 2016
Completion: Mar 8, 2020
NCT02872103
Placebo-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy
Phase: Phase 3
Start: Aug 31, 2016
Completion: Dec 20, 2017
NCT03252431
Neulasta-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy
Start: Apr 12, 2018
Completion: Mar 5, 2020
NCT04174599
Study to Compare the Efficacy and Safety of F-627 and GRAN®
Completion: Jun 19, 2019
NCT04056975
Study of A-319 in Patients With Relapsed or Refractory B-cell Lymphoma
Start: Sep 15, 2019
Completion: Jan 27, 2022
NCT04498377
Study of F-652 (IL-22:IgG2 Fusion Protein) in Patients With Moderate to Severe COVID-19
Start: Jan 26, 2021
Completion: Mar 24, 2021
NCT05205668
Study of F-652 in Subjects With Corona Virus Disease 2019 (COVID-19) Pneumonia
Start: Apr 8, 2022
Completion: Apr 8, 2023